EUVIMEDEUVIMED entdecken
Crossref

Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK

Fredrik Borgström, Mattias Lorentzon, Helena Johansson, Nicholas C Harvey, Eugene McCloskey, Damon Willems, Douglas Knutsson, John A Kanis

Osteoporosis International · 2024

DOI: 10.1007/s00198-024-07251-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Osteoporosis International, 2024. Verfasst von Fredrik Borgström und 7 weiteren Autor:innen. Beteiligte Einrichtung: Quantify Research, Stockholm, Sweden. fredrik.borgstrom@quantifyresearch.com. Hauptthemen laut MEDLINE: Teriparatide, Cost-Benefit Analysis, Bone Density Conservation Agents, Osteoporotic Fractures. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: UCB, Amgen, Osteoporosis Research Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sequential romosozumab-to-alendronate or sequential teriparatide-to-alendronate can be a cost-effective treatment option for postmenopausal women at very high risk of fracture. PURPOSE: To estimate the 10-year probability of a major osteoporotic fracture (MOF) at which sequential treatment with romosozumab or teriparatide followed by alendronate, compared with alendronate alone, becomes cost-effective in a UK setting. METHODS: A microsimulation model with a Markov structure was used to simulate fractures, costs, and quality-adjusted life years (QALYs), in women receiving sequential treatment with either romosozumab or teriparatide followed by alendronate, compared with alendronate alone. Patients aged 50 to 90 years with a recent MOF, hip or spine fracture were followed from the start of a 5-year treatment until the age of 100 years or death. The analysis had a healthcare perspective. Efficacy of romosozumab, teriparatide and alendronate was derived from phase III randomised controlled trials. Resource use and unit costs were derived from the literature. Cost-effectiveness intervention threshold (CEIT), defined as the 10-year probability of a major osteoporotic fracture at which treatment becomes cost-effective, was compared with clinically appropriate intervention thresholds for bone-forming treatment in women with very high fracture risk as recommended by the UK National Osteoporosis Guideline Group (NOGG). RESULTS: The base case analysis showed that sequential romosozumab-to-alendronate treatment was cost-effective from a 10-year MOF probability of 18-35% and above depending on age and site of sentinel fracture at a willingness to pay (WTP) of £30,000. For teriparatide-to-alendronate, treatment was cost-effective at a 10-year MOF probability of 27-57%. The results were sensitive to pricing of the drugs but relatively insensitive to treatment duration, romosozumab persistence assumptions, and site of sentinel fracture. The CEITs for romosozumab-to-alendronate treatment were lower than the clinical thresholds from the age of 70 years meaning that treatment could be considered both cost-effective and aligned with the NOGG treatment guidelines. By contrast, for teriparatide-to-alendronate the CEITs were higher than the clinical thresholds irrespective of age. However, cost-effective scenarios were found in the presence of strong clinical risk factors in addition to a recent sentinel fracture. CONCLUSION: The results of this study indicate that sequential romosozumab-to-alendronate or teriparatide-to-alendronate treatment can be a cost-effective treatment option for postmenopausal women at very high risk of fracture.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TeriparatideCost-Benefit AnalysisBone Density Conservation AgentsOsteoporotic FracturesOsteoporosis, PostmenopausalAlendronateQuality-Adjusted Life YearsAntibodies, MonoclonalMarkov ChainsDrug CostsHumansFemaleAgedMiddle AgedAged, 80 and overUnited KingdomDrug Therapy, CombinationDrug Administration ScheduleModels, Econometric

Stichwörter der Autor:innen

Cost-effectivenessEconomic evaluationFRAXIntervention thresholdsMarkov microsimulation modelOsteoporosisRecent fracture

Substanzen

TeriparatideBone Density Conservation AgentsromosozumabAlendronateAntibodies, Monoclonal

Autor:innen und Institutionen

  • Quantify Research, Stockholm, Sweden. fredrik.borgstrom@quantifyresearch.com.
  • Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
  • Sahlgrenska Osteoporosis Centre, Institute of Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK.
  • NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK.

Förderung

  • UCB
  • Amgen
  • Osteoporosis Research Ltd

Zitieren

APA

Borgström, F., Lorentzon, M., Johansson, H., Harvey, N. C., McCloskey, E., Willems, D., Knutsson, D., & Kanis, J. A. (2024). Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK. Osteoporosis International. https://doi.org/10.1007/s00198-024-07251-w

Vancouver

Borgström F, Lorentzon M, Johansson H, Harvey NC, McCloskey E, Willems D, et al. Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK. Osteoporosis International. 2024. doi:10.1007/s00198-024-07251-w

BibTeX
@article{Borgstrm2024,
  author = {Borgström, Fredrik and Lorentzon, Mattias and Johansson, Helena and Harvey, Nicholas C and McCloskey, Eugene and Willems, Damon and Knutsson, Douglas and Kanis, John A},
  title = {Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK},
  journal = {Osteoporosis International},
  year = {2024},
  doi = {10.1007/s00198-024-07251-w}
}
Kostenlos starten →